MRK: Obama budget creates regulatory pathway for biogenerics
Obama budget creates regulatory pathway for biogenerics
Previously, there was no mechanism for generic biologic drugs to be approved - which meant companies like Merck don't face generic competition. But Obama's budget proposes to change that.